News | February 07, 2025
Merck reports 2024 sales at $64.2 billion
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Branded formulation business continues to perform well across domestic and export markets
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
PAT after MI is Rs. 41 crore which is 162% increase
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
Subscribe To Our Newsletter & Stay Updated
